JP2024539506A5 - - Google Patents

Info

Publication number
JP2024539506A5
JP2024539506A5 JP2024548066A JP2024548066A JP2024539506A5 JP 2024539506 A5 JP2024539506 A5 JP 2024539506A5 JP 2024548066 A JP2024548066 A JP 2024548066A JP 2024548066 A JP2024548066 A JP 2024548066A JP 2024539506 A5 JP2024539506 A5 JP 2024539506A5
Authority
JP
Japan
Prior art keywords
antigen
seq
binding fragment
antibody
bcma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/040573 external-priority patent/WO2023068382A2/en
Publication of JP2024539506A publication Critical patent/JP2024539506A/ja
Publication of JP2024539506A5 publication Critical patent/JP2024539506A5/ja
Pending legal-status Critical Current

Links

JP2024548066A 2021-10-20 2022-10-19 Bcmaを標的とする組成物及びその使用方法 Pending JP2024539506A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163257822P 2021-10-20 2021-10-20
US202163257846P 2021-10-20 2021-10-20
US63/257,822 2021-10-20
US63/257,846 2021-10-20
PCT/JP2022/040573 WO2023068382A2 (en) 2021-10-20 2022-10-19 Compositions targeting bcma and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024539506A JP2024539506A (ja) 2024-10-28
JP2024539506A5 true JP2024539506A5 (cg-RX-API-DMAC7.html) 2025-09-18

Family

ID=84361139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548066A Pending JP2024539506A (ja) 2021-10-20 2022-10-19 Bcmaを標的とする組成物及びその使用方法

Country Status (14)

Country Link
US (2) US12290531B2 (cg-RX-API-DMAC7.html)
EP (1) EP4419561A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024539506A (cg-RX-API-DMAC7.html)
KR (1) KR20240099161A (cg-RX-API-DMAC7.html)
AR (1) AR127408A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022372894A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236038A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001225A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024004796A2 (cg-RX-API-DMAC7.html)
IL (1) IL311837A (cg-RX-API-DMAC7.html)
MX (1) MX2024004365A (cg-RX-API-DMAC7.html)
PE (1) PE20242001A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330612A (cg-RX-API-DMAC7.html)
WO (1) WO2023068382A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3253069A1 (en) * 2022-05-31 2023-12-07 Oncopeptides Innovation 1 Ab NEW POLYPEPTIDES
CN116574194A (zh) * 2022-06-02 2023-08-11 深圳普瑞金生物药业股份有限公司 嵌合抗原受体及其用途
JP2026512487A (ja) * 2023-04-18 2026-04-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Bcmaキメラ抗原受容体及びその使用
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えctla4ポリペプチドおよびその製造方法
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ513356A (en) 1999-02-05 2004-01-30 Univ Leiden Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
WO2001009300A2 (en) 1999-08-02 2001-02-08 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3053932B1 (en) 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
MA45498A (fr) * 2016-06-16 2019-04-24 Memorial Sloan Kettering Cancer Center Cellules treg génétiquement modifiées
SG11201900885VA (en) * 2016-08-01 2019-02-27 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JP7240335B2 (ja) * 2017-06-20 2023-03-15 テネオワン, インコーポレイテッド 抗bcma重鎖のみ抗体
WO2019099707A1 (en) * 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
CN113272320A (zh) 2018-11-19 2021-08-17 得克萨斯大学体系董事会 自杀基因
WO2020227446A1 (en) 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
JP2022548902A (ja) 2019-09-18 2022-11-22 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Bcma陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法
CN113248611B (zh) * 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用

Similar Documents

Publication Publication Date Title
JP2022523781A5 (cg-RX-API-DMAC7.html)
CN108610420B (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
US12441798B2 (en) CD123 binding proteins and related compositions and methods
JP7303749B2 (ja) Tim-1を標的とするキメラ抗原受容体
JP2021520788A5 (cg-RX-API-DMAC7.html)
US12534532B2 (en) CLL1-targeting antibody and application thereof
JP2019515661A5 (cg-RX-API-DMAC7.html)
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
CA3032581A1 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
CN112912401B (zh) 抗-l1细胞粘附分子抗体或其抗原结合片段及包含其的嵌合抗原受体
KR20190133017A (ko) 개선된 항원 결합 수용체 구성
JP2019516352A5 (cg-RX-API-DMAC7.html)
JP2017524367A5 (cg-RX-API-DMAC7.html)
KR20190133723A (ko) 개선된 항원 결합 수용체
KR20230129983A (ko) 조작된 세포 요법을 위한 표적화된 사이토카인 구축물
CA3030837A1 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
HRP20221348T1 (hr) Kimerni receptori i postupci njihove uporabe
JP2017527271A5 (cg-RX-API-DMAC7.html)
JP2017530694A5 (cg-RX-API-DMAC7.html)
AU2020378263A1 (en) BCMA-targeted CAR-T cell therapy of multiple myeloma
JP2021530233A5 (cg-RX-API-DMAC7.html)
JP2023518930A5 (cg-RX-API-DMAC7.html)
JP2024541476A5 (cg-RX-API-DMAC7.html)
CA3217614A1 (en) Chimeric receptors and methods of use thereof
JP2025513427A5 (cg-RX-API-DMAC7.html)